Search research articles
Contact Us
Filters
Showing results (451-460 of 471) with videos related to
Page
of 48
Sort By:
Blood
|
July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Jonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
American Journal of Hematology
|
January 11, 2021
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
Maria Eleni Drosou, Lisa E Vaughan, Eli Muchtar, et al.
Haematologica
|
March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone
Ricardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Cancer Journal
|
April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T Vogl, David Dingli, Robert Frank Cornell, et al.
American Journal of Hematology
|
April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia
Jithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
American Journal of Hematology
|
October 29, 2017
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Jithma P Abeykoon, Jonas Paludo, Rebecca L King, et al.
Blood
|
July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
Udit Yadav, Shaji K Kumar, Linda B Baughn, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Leukemia
|
February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Page
of 48
Search research articles
Search
Showing results (451-460 of 471) with videos related to
Sort By:
Page
of 48
Blood
|
July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Jonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
American Journal of Hematology
|
January 11, 2021
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
Maria Eleni Drosou, Lisa E Vaughan, Eli Muchtar, et al.
Haematologica
|
March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone
Ricardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Cancer Journal
|
April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dan T Vogl, David Dingli, Robert Frank Cornell, et al.
American Journal of Hematology
|
April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia
Jithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
American Journal of Hematology
|
October 29, 2017
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Jithma P Abeykoon, Jonas Paludo, Rebecca L King, et al.
Blood
|
July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
Udit Yadav, Shaji K Kumar, Linda B Baughn, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Leukemia
|
February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Page
of 48